Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver
Status:
No longer available
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Severe veno-occlusive disease (VOD) of the liver is a life threatening complication of blood
and marrow transplantation. Treatment with currently available (Food and Drug Administration
[FDA] approved) agents fails in most cases. Recently conducted clinical studies indicate that
patients benefit from defibrotide, a non-FDA approved agent. This protocol has been developed
not with a research intent, but rather to ensure that defibrotide is used by the blood and
marrow transplant programs at Children's Healthcare of Atlanta and at Emory University in a
safe, effective and ethical manner.